Current therapies and new developments in NASH

Jean Francois Dufour, Quentin M. Anstee, Elisabetta Bugianesi, Stephen Harrison, Rohit Loomba, Valerie Paradis, Herbert Tilg, Vincent Wai Sun Wong, Shira Zelber-Sagi

Research output: Contribution to journalReview articlepeer-review

Abstract

Non-alcoholic steatohepatitis is becoming the most importance etiology for advanced liver disease. The field made important progresses in the last years. The complexity of the pathophysiology of NASH is better understood. Multiple non-invasive criculating and imaging biomarkers have been tested. The importance of lifestyles has been reconised and several drugs are tested in clinical trials. This review adresses the challenges that face health care professionals in the management of NASH patients.

Original languageEnglish
Article number326874
JournalGut
DOIs
StateAccepted/In press - 2022

Bibliographical note

Publisher Copyright:
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Current therapies and new developments in NASH'. Together they form a unique fingerprint.

Cite this